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Abstract
Uridine phosphorylase (UPP) is a central enzyme in the pyrimidine salvage pathway, catalyzing the reversible phosphorolysis
of uridine to uracil and ribose-1-phosphate. Human UPP activity has been a focus of cancer research due to its role in
activating fluoropyrimidine nucleoside chemotherapeutic agents such as 5-fluorouracil (5-FU) and capecitabine.
Additionally, specific molecular inhibitors of this enzyme have been found to raise endogenous uridine concentrations,
which can produce a cytoprotective effect on normal tissues exposed to these drugs. Here we report the structure of hUPP1
bound to 5-FU at 2.3 A ˚ resolution. Analysis of this structure reveals new insights as to the conformational motions the
enzyme undergoes in the course of substrate binding and catalysis. The dimeric enzyme is capable of a large hinge motion
between its two domains, facilitating ligand exchange and explaining observed cooperativity between the two active sites
in binding phosphate-bearing substrates. Further, a loop toward the back end of the uracil binding pocket is shown to
flexibly adjust to the varying chemistry of different compounds through an ‘‘induced-fit’’ association mechanism that was
not observed in earlier hUPP1 structures. The details surrounding these dynamic aspects of hUPP1 structure and function
provide unexplored avenues to develop novel inhibitors of this protein with improved specificity and increased affinity.
Given the recent emergence of new roles for uridine as a neuron protective compound in ischemia and degenerative
diseases, such as Alzheimer’s and Parkinson’s, inhibitors of hUPP1 with greater efficacy, which are able to boost cellular
uridine levels without adverse side-effects, may have a wide range of therapeutic applications.
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Introduction
Uridine phosphorylase (UPP; EC 2.4.2.3) is a ubiquitous
enzyme that catalyzes the reversible phosphorolysis of uridine
and analogous compounds to uracil and ribose-1-phosphate,
playing an important role in pyrimidine salvage and regulation of
uridine homeostasis [1–3]. Most mammals, including humans,
possess two isoforms of the enzyme, UPP1 [4] and UPP2 [5], of
which UPP1 has been much more extensively studied. Interest in
understanding the activity of human uridine phosphorylase
(hUPP) stems from its role in the activation of pyrimidine
nucleoside analogues used in chemotherapy, such as 5-fluorouracil
(5-FU) [6] and its prodrug, capecitabine. In this case, the enzyme
converts 5-FU to 5-fluorouridine, which is subsequently further
activated by uridine kinase to create 5-fluorouridine monophos-
phate. Multiple further downstream metabolites of 5-FU exert
anti-cancer activity through disruption of RNA synthesis,
misincorporation into DNA, or inhibition of thymidylate synthase,
the activity of which is essential for DNA synthesis and repair.
Other research has shown that some tumours have increased levels
of hUPP activity, a finding that may partly explain the tissue
selectivity of these chemotherapeutic agents [7,8]. More recent
investigations have explored using hUPP inhibitors to boost
cellular uridine concentrations, as a means of limiting the toxic
effects of fluoropyrimidine nucleoside exposure to healthy tissues
during the course of treatment [9,10]. Compounds such as 5-
benzylacyclouridine (BAU) [11] have been tested for their ability
to increase the maximum tolerated dosage and therapeutic index
of 5-FU through this uridine-mediated cyto-protective phenome-
non [12].
A fundamental understanding of the underlying structural
mechanisms behind the catalytic activity of this enzyme has been
established through extensive structural analysis of bacterial UPPs,
starting with E. coli UPP (EcUPP) [13–16] and then the closely-
related S. typhimurium homologue [17–19]. More recently, multiple
structures of the human enzyme, hUPP1 [20], its bovine
homologue, bUPP1 [21], and a UPP from the parasitic protozoa,
Trypanosoma brucei [22], have been determined. These structures
have revealed unexpected differences in variations of this enzyme.
Most interestingly, the hexameric, trimer-of-dimers organization
of prokaryotic UPPs has been dissociated in favour of strictly
dimeric complexes in eukaryotic organisms. These studies are also
uncovering unique differences in the molecular details of the
architecture of these enzymes that may be critical to discovering
novel compounds with increased efficacy in modulating this
enzyme’s activity for the development of better therapeutic
regimens.
Here we present the crystallographic structure of hUPP1 bound
to 5-FU. This structure reveals previously unknown conforma-
tional flexibility in loops proximate to this enzyme’s active sites
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protein. These insights regarding the structural dynamics of
hUPP1 will be useful both for improving our understanding of this
enzyme’s role in the activation of fluoropyrimidines and in
identifying strategies for more effectively modulating this protein’s
activity through medications.
Results
hUPP1 structure when bound to 5-fluorouracil
One of the unexpected findings of the first structures of hUPP1
was the discovery that the domains of the enzymatic dimer are
flexibly linked, allowing an interdomain motion from an ‘‘open’’
ligand-free conformation to a ‘‘closed’’ catalytically-active struc-
ture [20]. The structure of hUPP1 bound to 5-FU provides further
insight into this motion, having been crystallized in a transitional,
intermediate position roughly 80% of the way from ‘‘open’’ to
‘‘closed’’ (Figure 1). The observed rotational movement hinges
around a stable pivot point on one face of the enzyme that
contains an extensive interdomain interface formed by overlap-
ping strand-turn-strand elements that are not present in
prokaryotic homologues [20]. The constraints imposed by the
hexameric ring structure of bacterial UPPs likely prevent the
occurrence of a similar phenomenon in these enzymes and it has
not been observed in any of the structures of these proteins. This
interdomain motion may have interesting consequences on the
kinetics and regulation of dimeric eukaryotic enzymes relative to
their better-characterized prokaryotic counterparts. The observed
structural flexiblity links the two active sites and predicts that
substrates that stablize the ‘closed’ conformation of the enzyme by
associating with residues from both protein chains will coopera-
tively increase the affinity of other substrates that also bind across
the dimer interface. Indeed, cooperative binding of phosphate and
ribose-1-phosphate has recently been confirmed through extensive
in vitro analysis of the biochemistry of recombinant hUPP1 [23].
It is notable, that the interdomain motion between folds within a
hUPP1 dimer is accompanied by nearly imperceptible changes in
the conformational structure of the individual domains. The
overall R.M.S.D. of main chain atoms from ligand-free to BAU-
bound for aligned monomers is less than 1.00 A ˚. The differences
are even less comparing BAU-bound and 5-FU-bound enzymes,
with structural differences limited almost exclusively to a loop
lining the back side of the active site pocket (Figure 1, magenta
highlight).
Coordination of 5-FU within the hUPP1 active site
Analysis of electron density distribution at the enzyme’s active
site reveals density in omit maps consistent with bound 5-FU
(Figure 2). The coordination of 5-FU by the protein is exactly as
seen previously for E. coli UPP with 5-FU [15], S. typhimurium UPP
with 5-FU [18], and bovine UPP1 with 5-FU [21]. The binding of
uracil is stabilized by a network of hydrogen-bonds created by
Gln217, Arg219, Arg275 and a single deeply buried water
molecule. All of these elements are strictly conserved among
known UPPs and have been proposed to form a UPP-specificity
motif for distinguishing those enzymes with uridine preference
from among the larger family of nucleoside phosphorylases [22].
The fluorine moiety of 5-FU forms a hydrogen bond with Ser142
and is otherwise closely encased in a cluster of hydrophobic
residues including Leu272, Leu273 and Ile281. These latter
residues, which are key to binding the benzyl modification of high
affinity inhibitors such as BAU, are also the only distinguishing
active site residues when comparing eukaryotic and prokaryotic
enzymes (equivalent E. coli residues are Ile 220, Val221 and P229).
This is an important consideration when contemplating generating
selectivity in such competitive inhibitors between the two enzymes,
Figure 1. Structural comparison of hUPP1 with varying ligands. Overlay of the structures of hUPP1 bound to 5-FU, BAU, or ligand-free (APO)
reveals the high degree of retention of the global fold of the enzyme when binding either substrate or inhibitor. The position of the two 5-FU
molecules within the symmetric active sites at the dimer interface is also shown. In this illustration, the green/yellow monomers are least-squares
aligned (R.M.S.D.s shown in angstroms) and the resulting displacement of the backbone traces of the partnering chains (arrows) reveals the
interdomain flexibility of hUPP1. Between aligned monomers binding either 5-FU or BAU, there is a noticeable structural difference only in the
conformation of a loop proximate to the active site (magenta).
doi:10.1371/journal.pone.0012741.g001
Structure of hUPP1 with 5-FU
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targeting only bacterial homologues of this protein [19].
Substrate-induced conformational changes
Comparison of the architectures of BAU-bound and 5-FU
bound monomers of hUPP1 reveals that substantial structural
changes are restricted to a single loop region toward the back side
of the active site. This loop has been demonstrated in E. coli UPP
to undergo an ‘induced-fit’ restructuring from a flexible,
disordered form to an active-site capping position upon ligand
binding [15]. In contrast, earlier structures of hUPP1 had revealed
no conformational differences between BAU-bound and ligand-
free states for this loop and comparably low thermal factors in both
structures for this region of the protein, leading to the suggestion
that this loop might be rigid in the human enzyme [20]. The 5-
FU-bound structure shows that this conclusion is inaccurate, as the
loop clearly closes around the small fluorine moiety of 5-FU
(Figure 3A). While this flap-like structure is clearly less mobile in
the human enzyme than in its prokaryotic equivalent, its retained
ability to adjust its shape to accommodate various altered chemical
forms of uracil/uridine has important implications for under-
standing how to strategically exploit this dynamic element in the
design of better enzyme inhibitors. It is certainly noteworthy that
BAU binds hUPP1 with this loop in nearly an identical
conformation as found in the ligand-free structure, suggesting
that this compound binds to a naturally occurring, low-energy
state of the enzyme (Figure 3B). As this region includes the three
active site-distinguishing hydrophobic residues mentioned earlier,
Figure 2. 5-Fluorouracil binding to hUPP1. (A) 5-FU is coordinated by residues restricted to the individual monomers of the hUPP1 dimer, in
contrast to the binding of BAU that traverses the dimer interface. As expected, Gln217 and Arg219, the key uridine-discriminating residues, form
multiple hydrogen bonds with one face of the uracil base. This face also includes a well-coordinated, buried water molecule that associates with 5-FU
and creates stabilizing bonds with both Gln217 and Arg275. Additional favourable interactions may be formed by both the backbone carbonyl and
side chain hydroxyl groups of Thr141, although the geometry observed in the crystal structure is not consistent with hydrogen bonding. The fluorine
moiety resides in a hydrophobic pocket created by Leu272, Leu273 and Ile281, and forms a hydrogen bond with Ser142. Electron density from a 2Fo-
Fc map contoured at 1.5s is shown for the ligand (blue wire). (B) Surface representation from the same perspective emphasizes the depth and fit of
the active site for the pyrimidine substrate. The position of Phe213, which was omitted from (A) for clarity, is also illustrated. This residue caps the
active site and forms hydrophobic, herringbone stacking interactions with the uracil ring. (C) Schematic map of the contacts between hUPP1 and 5-
FU as analyzed by LigPlot [37].
doi:10.1371/journal.pone.0012741.g002
Figure 3. Conformational dynamics of a hUPP1 active site loop. (A) Comparison of the structure of the loop lining the back of the hUPP1
active site when bound to 5-FU (green), BAU (lime), or ligand-free (yellow), reveals that this region is somewhat mobile and able to close around
substrate upon its binding. (B) Overlay of the BAU molecule with the known structures of hUPP1 shows that the benzyl moiety of this inhibitor
displaces Ile281 from its normal substrate binding position to accommodate the extra bulkiness of this molecule. It is notable how similar the BAU-
bound and ligand-free conformations of hUPP1 are, suggesting that BAU fits the naturally occurring structure of the protein in the absence of
substrate. (C) While the new structure of hUPP1 reveals some degree of flexibility in the back-side active site loop, the conformational range of this
region of hUPP1 is substantially less than that of the equivalent part of E. coli UPP, which closes more tightly when bound to 5-FU (yellow) and opens
wider in the absence of ligand (orange) when compared with its BAU-inhibited structure (red). The increased rigidity of the human enzyme is likely
due to the insertion of two additional residues into this loop region, including a proline (inset).
doi:10.1371/journal.pone.0012741.g003
Structure of hUPP1 with 5-FU
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selective inhibition of only one homologue over others (Figure 3C).
As the interdomain hinge is in a transitional, intermediate state
in the 5-FU-bound structure of hUPP1, it was expected that there
would also be substantial conformational changes in the active site
residues that reach from one domain to influence ligand binding in
the partnering domain’s active site. Earlier studies of hUPP1
suggested that hinge closure was driven by the creation of
energetically favourable contacts between residues from the one
chain with the small molecules bound to the other chain’s active
site [20]. Specifically, in the BAU-bound structure of hUPP1,
three partner-subunit residues assisted in the coordination,
respectively, of the benzyl moiety (Tyr35), the ribose group
(His36), and phosphate ion (Arg94). These chemical groups are all
absent from the 5-FU-bound structure, eliminating every inter-
domain protein-ligand interaction. In spite of the lack of these
stabilizing associations, all of these residues adopt conformations
similar to those observed in the BAU-bound structure (Figure 4).
This suggests that the active, ligand-binding conformations of
these residues are low energy, naturally-adopted rotamers, thus
favouring substrate association and catalysis of phosphorolysis. It is
also interesting that while both the BAU-bound and 5-FU
structures were crystallized under very similar conditions, only
the former was found to have bound phosphate, presumably
chelated from trace contamination in the purification or
crystallization solutions. This is likely a result of the benzyl and
sugar groups of the BAU inhibitor stabilizing a fully ‘‘closed’’
enzyme configuration in which the two phosphate-binding
arginine residues are in perfect alignment for ion coordination.
Consistent with 5-FU not effectively stabilizing this interdomain
conformation, the resulting structure is found partially open and
the phosphate site unoccupied.
Discussion
Human uridine phosphorylase has been of interest to clinical
researchers for several decades now due to its important role in
activating front-line chemotherapeutic fluoropyrimidine nucleo-
sides [1]. It has also been studied as the molecular target for the
design of specific inhibitors intended to boost plasma and tissue
uridine levels in order to rescue normal tissues from these cytotoxic
compounds [10]. The structure of hUPP1 in complex with 5-FU
reported here clarifies several aspects regarding the conformation-
al dynamics of this enzyme, an understanding of which impacts the
rational design of better inhibitors with improved affinity and
selectivity. In contrast with better characterized microbial UPPs,
the dimeric architecture of the human enzyme leads to
interdomain motions that ‘‘close’’ the protein around substrates
and ‘‘open’’ to facilitate product release. This observation suggests
a new avenue for the development of a novel class of UPP
inhibitors that sterically block the closing of this enzyme. Even a
small obstruction that maintains the separation of Arg94 from
Arg138 (as produced by crystal contacts in the 5-FU-bound
structure) may effectively completely disrupt the enzyme’s activity
by preventing phosphate coordination and in turn, catalyzed
phosphorolysis of uridine. Further, understanding the conforma-
tional flexibility within the backside loop proximal to the active site
provides new approaches as to how to rationally redesign the
hydrophobic modifications of acyclouridine analogues to most
effectively maximize favourable interactions with low energy
configurations of this part of the enzyme. Given recent reports
indicating that BAU may also affect human aldehyde oxidase
activity [24], improving this compound’s selectivity may be critical
to creating a therapeutically valuable medicine with limited side-
effects.
Figure 4. Inter-domain flexibility of hUPP1. Illustration highlights conformational changes at the dimer interface proximate to the active site,
overlaying the 5-FU-bound structure (gold), the BAU-bound structure (orange), and ligand-free structure (red). Despite a lack of molecular contacts
between residues from the partnering subunit and the 5-FU ligand, the critical residues for binding natural substrates adopt conformations close to
those seen in the BAU-bound structure, where they are stabilized by the formation of favourable molecular interactions, and not the conformations
revealed in the ligand-free structure. The location of the phosphate ion from the BAU-bound structure is shown for orientation, but not found to be
occupied in the 5-FU-bound structure.
doi:10.1371/journal.pone.0012741.g004
Structure of hUPP1 with 5-FU
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new roles for uridine in the cytoprotection of tissues are being
discovered. Recent reports have shown that uridine phosphor-
ylase activity is under the regulation of a number of hepatic
nuclear receptors, suggesting a link between lipid and uridine
metabolism [25,26]. This is increasingly of interest given the
rising prevalence of fatty liver disease among populations.
Uridine has also been found to protect astrocytes from cellular
death under energy-limiting conditions, such as ischemia
[27,28]. Further, administration of uridine in combination with
docosahexaenoic acid is being tested as a potential treatment for
both Alzheimer’s disease [29] and Parkinson’s disease [30].
Thus, targeting human UPP to raise endogenous uridine levels
may prove valuable as a more general approach toward the
cytoprotection of a variety of cells, beyond its original
application as a means of rescuing tissues exposed to
fluoropyrimidines during the course of chemotherapeutic
treatment.
Materials and Methods
Protein production and purification
Production and isolation of hUPP1 was conducted as
previously reported [20,31] and followed standard laboratory
protocols for recombinant bacterial protein expression and
purification. In brief, pQE plasmid containing an N-terminally
six histidine-tagged construct of the enzyme was transformed into
BL21(DE3) E. coli. Freshly transformed colonies were cultured in
Terrific Broth and induced with 0.1 mM isopropyl-b-D-thioga-
lactopyranoside (IPTG) at an O.D. of 1.0. Growth was continued
overnight at 18uC. Cells were harvested and resuspended in
50 mM Tris buffer pH 8.0, 300 mM KCl, 10% glycerol with
20 mM imidazole. The bacteria were then disrupted by
sonication on ice and membranes with other insoluble material
were pelleted by high speed centrifugation (100,0006g). Recom-
binant hUPP1 was subsequently purified from the resulting
supernatant using Ni-NTA affinity chromatography and batch
eluted with 500 mM imidazole added to the sonication buffer
above. Further purification was conducted using gel filtration
chromatography over Superdex 200 resin equilibrated in
300 mM KCl, 50 mM Tris buffer pH 8.0 with 1 mM Tris (2-
carboxy-ethyl) phosphine (TCEP). The final sample was verified
to be homogenous by SDS-PAGE experiments and used directly
for crystallization.
Crystallization
Purified hUPP1 at 4 mgs/mL was supplemented with 1 mM 5-
FU (Sigma) and subject to crystallization screening in conditions
similar to those previously identified to successfully crystallize
hUPP1 with BAU [20]. Large rod-shaped crystals formed in 17%
PEG 3350, 100 mM Bis-Tris buffer pH 5.5, and 160 mM MgCl2.
Crystals were frozen by submersion in liquid nitrogen after a few
seconds incubation in cryoprotectant containing the above
constituents supplemented with 25% ethylene glycol and 5 mM
5-FU.
Data collection/processing and structure determination
Data was collected at SSRL beamline 7-1 as summarized in
Table 1. A complete, high quality dataset to 2.3 A ˚ resolution was
collected. This data was processed and reduced by the HKL2000
package with Denzo and Scalepack [32]. The 5-FU-bound hUPP1
crystallized in the same orthogonal space group (P212121)a s
crystals of this protein in complex with BAU and possessed low
mosaicity. Molecular replacement phasing of the data obtained on
hUPP1 with 5-FU was successful through Molrep [33] using
monomers of hUPP1 with BAU as a search model (PDB ID:
3EUF) [20]. Solution phases were sufficient to resolve unambig-
uous density for the four unmodeled 5-FU ligands (one per protein
chain). Rounds of model building and refinement were performed
using Coot [34] and Refmac [33]. As with the BAU-bound
structure, there is a lack of electron-density for the first 15 residues
of hUPP1, the N-terminal cloning artifact residues
‘MRGSHHHHHHGSPGLQEF’, and the final two C-terminal
residues. Tight non-crystallographic symmetry restraints (between
4 chains) were retained for the main chain loop residues 78–84 due
to the low quality of the electron-density map in this region of the
protein. The final structure was refined with Refmac to an Rfactor/
Rfree of 22.5%/27.7%, with approximately 89% of residues in
most favourable regions of the Ramachandran plot as analyzed by
Procheck [35]. The model was further validated using Molprobity
[36], scoring in the 98
th percentile. Figures were rendered using
ICM Browser-Pro (Molsoft) or LigPlot [37]. The atomic
coordinates and structure factors have been deposited in the
Protein Data Bank (3NBQ).
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